Synchron Inc.
Endovascular neural interface could help paralyzed patients
This article was originally published in Start Up
Executive Summary
Synchron Inc. is developing what it believes is the first minimally invasive implantable brain device that could help paralyzed patients: its neural interface, Stentrode, consists of an electrode array built onto a self-expanding stent that is implanted in a cerebral blood vessel. Once the stent is implanted, the array is designed to record local neuronal activity, then translate that activity into a signal that could be used to manipulate mobility-assist devices and return movement to the paralyzed user.
You may also be interested in...
Recent And Upcoming FDA Advisory Committee Meetings
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.
OIG: FDA’s EUA Approach Allowed Bad Tests To Reach Market
A review by a government watchdog found the FDA’s review process for COVID-19 diagnostics was plagued by issues including allowing low-quality tests to slip through, high reviewer workloads, and manufacturer frustration.
TCT 2022: Trial Of Boston Scientific’s TAVR Embolic Protector Misses Endpoint, But May Offer 'Hope'
New trial data shows Boston Scientific’s Sentinel cerebral embolic protection device may reduce the risk of disabling stroke, but it does not appear to reduce the overall risk of stroke.